相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Influence of Surgical Procedures on Serum Paraoxonase-1-Related Variables and Markers of Inflammation in Hospitalized Patients
Simona Iftimie et al.
JOURNAL OF INVESTIGATIVE SURGERY (2021)
Association of carotid intima media thickness with atherogenic index of plasma, apo B/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease
Reza Fadaei et al.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY (2019)
Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity A meta-analysis
Guangrong Dai et al.
MEDICINE (2019)
Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population
Daniel F. Mazo et al.
ANNALS OF HEPATOLOGY (2019)
Paraoxonase 1 Activity, Polymorphism and Atherosclerosis Risk Factors in Patients Undergoing Coronary Artery Surgery
Anna Wysocka et al.
JOURNAL OF CLINICAL MEDICINE (2019)
The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: The missing link between environmental and genetic regulation
Abdolkarim Mahrooz et al.
CLINICAL BIOCHEMISTRY (2019)
Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease
Chrysan J. Mohammed et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis
Qianyi Wang et al.
HEPATOLOGY INTERNATIONAL (2019)
Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders
Maria Joao Meneses et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein
James P. Corsetti et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Laurent Castera et al.
GASTROENTEROLOGY (2019)
Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol
Eline H. van den Berg et al.
JOURNAL OF LIPID RESEARCH (2019)
Paraoxonases Activities and Polymorphisms in Elderly and Old-Age Diseases: An Overview
Debora Levy et al.
ANTIOXIDANTS (2019)
Current and future pharmacological therapies for NAFLD/NASH
Yoshio Sumida et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Paraoxonase 1 (PON1)-L55M among common variants in the coding region of the paraoxonase gene family may contribute to the glycemic control in type 2 diabetes
Abdolkarim Mahrooz et al.
CLINICA CHIMICA ACTA (2018)
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis
Zobair M. Younossi et al.
HEPATOLOGY (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
Arylesterase activity of Paraoxonase 1-prognostic factor for one-year survival in patients with acute myocardial infarction
Lorena Ciumarnean et al.
REVISTA ROMANA DE MEDICINA DE LABORATOR (2018)
Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance
Nelusha Shunmoogam et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2018)
Non-cardiometabolic comorbidities of non-alcoholic fatty liver disease
Mircea Vasile Milaciu et al.
BALNEO RESEARCH JOURNAL (2018)
Involvement of xanthine oxidase and paraoxonase 1 in the process of oxidative stress in nonalcoholic fatty liver disease
Bing Wang et al.
MOLECULAR MEDICINE REPORTS (2017)
Cytokines Genotype-Phenotype Correlation in Nonalcoholic Steatohepatitis
Ioana Corina Bocsan et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae
Handrean Soran et al.
CURRENT OPINION IN LIPIDOLOGY (2015)
Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles
Mike Mackness et al.
GENE (2015)
Serum Basal Paraoxonase 1 Activity as an Additional Liver Function Test for the Evaluation of Patients with Chronic Hepatitis
Anand K. Pyati et al.
JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH (2015)
Is the Non-Alcoholic Fatty Liver Disease Part of Metabolic Syndrome?
Sur Genel et al.
JOURNAL OF DIABETES & METABOLISM (2015)
Paraoxonase 1 and oxidative stress in paediatric non-alcoholic steatohepatitis
Sonal Desai et al.
LIVER INTERNATIONAL (2014)
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
Jessica K. Dyson et al.
FRONTLINE GASTROENTEROLOGY (2014)
Paraoxonase 1 (PON1) reduces macrophage inflammatory responses
Saar Aharoni et al.
ATHEROSCLEROSIS (2013)
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Paola Dongiovanni et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Distribution of Paraoxonase 1 polymorphisms and activities in obese patients
Lorena Ciumarnean et al.
REVISTA ROMANA DE MEDICINA DE LABORATOR (2013)
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin
Waleed Samy et al.
Arab Journal of Gastroenterology (2011)
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Vlad Ratziu et al.
JOURNAL OF HEPATOLOGY (2010)
Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment
Judit Marsillach et al.
LIPIDS IN HEALTH AND DISEASE (2010)
Serum paraoxonase 1 activity status in patients with liver disorders
Mungli Prakash et al.
Saudi Journal of Gastroenterology (2010)
分享论文
